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Background/Aims: Endoscopic papillary large-balloon 
dilation combined with limited endoscopic sphincterotomy 
(EPLBD+ES) is promising for the treatment of common bile 
duct (CBD) stones. The aim of this study was to clarify the 
recurrence rate and the risk factors for CBD stones after 
EPLBD+ES. Methods: In total, 100 patients who underwent 
EPLBD+ES from 2006 to 2007 were evaluated retrospec-
tively. One hundred and nine patients who were treated with 
endoscopic sphincterotomy (ES) from 2004 to 2005 were 
set as the historical control group. Various risk factors for 
the recurrence of bile duct stones were analyzed. Results: 
Of the 209 patients, the duration of follow-up was 32.5±4.5 
months in the EPLBD+ES group and 31.8±6.0 months in 
the ES group. The recurrence rate of CBD stones was 11.0% 
(11/100) in the EPLBD+ES group and 13.8% (15/109) in 
the ES group (p=0.546). The cumulative recurrence rate of 
stones was not signiﬁ  cantly different between the EPLBD+ES 
and ES groups (log rank, p=0.537). Univariate analysis 
showed that the diameter of the CBD (≥22 mm) was the only 
predictive variable that could differentiate recurrence from 
nonrecurrence in the EPLBD+ES group. Multivariate analy-
sis revealed that the diameter of the bile duct was the only 
risk factor for stone recurrence (p=0.022; odds ratio, 1.175; 
95% conﬁ  dence interval, 1.023 to 1.348). Conclusions: The 
recurrence rate of CBD stones after EPLBD+ES is compa-
rable to that of the ES group, and a dilated CBD appears to 
increase the risk of bile duct stone recurrence. (Gut Liver 
2012;6:107-112)
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INTRODUCTION
Since introduction of endoscopic sphincterotomy (ES) by 
Classen and Demling
1 and Kawai et al.
2 in 1974, ES has been the 
standard therapy for treatment of various cholangiopancreatic 
diseases. Although ES has many advantages, substantial com-
plications associated with ES have been reported. Acute pancre-
atitis, hemorrhage, duodenal perforation, and acute cholangitis 
are known to be short-term complications, and recurrence of 
stones and papillary stenosis are known to be long-term com-
plications of ES.
3-5
Endoscopic papillary balloon dilation (EPBD) was first de-
scribed by Staritz et al.
6 and has been advocated as an alter-
native to ES for facilitation of common bile duct (CBD) stone 
removal. The potential advantage of EPBD over ES is that it pre-
serves the function of the biliary sphincter and possibly reduces 
the long-term sequelae of ES. However, due to certain limita-
tions in the clinical setting in that the biliary opening is not 
enlarged to the same degree as with ES, mechanical lithotripsy 
is more frequently required for management of large stones.
7-9 
In addition, there have been a number of reports that EPBD was 
associated with a higher rate of post-procedure pancreatitis.
10 
Meanwhile, Ersoz et al.
11 have suggested that EPBD with a 
large balloon following conventional ES might be a very effec-
tive method for retrieval of bile duct stones that were difficult 
to extract by a standard procedure. According to a few recent 
reports, endoscopic papillary large balloon dilatation (EPLBD) 
combined with limited ES (EPLBD+ES) has a similar therapeutic 
effect and is relatively safe in terms of complications for treat-
ment of CBD stones.
12,13 Complications, such as hemorrhage and 
perforation, were less frequent in EPLBD+ES, compared with 
conventional ES.
14-16 
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of choledocholithiasis after ES is 5.8% to 24%.
17-21 There are 
many descriptions of short-term results of EPLBD+ES; however, 
little is known about mid-term or long-term complications, 
such as recurrence of choledocholithiasis after EPLBD+ES.
12-14,16 
We conducted this study in order to evaluate the recurrence rate 
of CBD stones between the EPLBD+ES group and the ES group, 
and to determine the risk factors associated with recurrence of 
bile duct stones after EPLBD+ES.
MATERIALS AND METHODS
A total of 100 patients with bile duct stones larger than 1 cm 
in diameter (51 men, 49 women; mean age, 70.9±10.3 years) 
who underwent EPLBD+ES from May 2006 to December 2007 
were studied retrospectively. A total of 109 patients with bile 
duct stones larger than 1 cm in diameter (48 men, 61 women; 
mean age, 71.9±12.9 years), who were treated with ES using a 
sphincterotome in a conventional manner from January 2004 
to August 2005, were set as a historical control group. Patients 
were followed up until December 2009 in the EPLBD+ES group 
and until May 2007 in the ES group, to match the duration of 
follow-up between the two groups. Recurrence of CBD stones 
is defined as recurrence after 6 months of treatment with 
EPLBD+ES or ES. Exclusion criteria for this study were as fol-
lows: 1) patients with hepatolithiasis; and 2) patients with re-
current bile duct stones which were detected less than 6 months 
after EPLBD+ES or ES.
All endoscopic retrograde cholangiopancreatography (ERCP) 
procedures were performed using side-viewing endoscopes (TJF-
240; Olympus Optical Co., Tokyo, Japan). These ERCPs were car-
ried out by experienced endoscopists. Precutting with a needle 
knife or guide wire technique was applied in cases of difficult 
CBD cannulation. In the EPLBD+ES group, EPLBD was per-
formed with a balloon dilator after small or medium ES. Once 
ES was completed, a guide wire was left in the biliary tree and 
a balloon dilator (CRE balloon; Boston Scientific Microvasive, 
Cork, Ireland) was advanced over the guide wire, positioning the 
middle portion of the balloon across the ampullary orifice. Un-
der endoscopic and fluoroscopic guidance, the balloon was then 
inflated gradually with diluted contrast media until the notch 
on the balloon disappeared. Once the notch disappeared, infla-
tion of the balloon was maintained for 30 to 60 seconds. A bal-
loon dilator between 12 to 20 mm in diameter was used and the 
diameter of the balloon was determined according to the size 
of the stones. In the ES group, medium or large-sized ES with a 
pull-type sphincterotome was performed according to the size 
of CBD stones. The size of sphincterotomy was categorized as 
large (to the upper margin of the papillary roof), medium (below 
the upper margin), or small. For stones that were too large for 
removal in one session, an endoscopic mechanical lithotripsy 
was attempted in order to fragment the stones. When incom-
plete stone removal was suspected at the end of the procedure, 
an endoscopic nasobiliary drainage or plastic stent was inserted 
in order to prevent cholangitis. 
The size and number of stones were documented on the chol-
angiogram after optimum opacification of the bile duct. Stone 
size was measured manually with the removed stone or assessed 
by comparison of the diameter of the stone with the shaft of the 
endoscope on the cholangiogram. In the same way, other fac-
tors including diameter and angulation were measured from the 
cholangiogram using PACS program (Infinitt, Seoul, Korea). The 
angulation was measured at the first angle from the ampullary 
orifice along the CBD. Complete stone removal was confirmed 
either by final cholangiogram just after ERCP or by follow-
up cholangiogram through the nasobiliary drainage catheter. 
All recurrent CBD stones were confirmed by ERCP. Risk factors 
for recurrence of bile duct stones and mean intervals between 
the time of initial treatment and the time of recurrence of CBD 
stones were analyzed. The protocol was approved by the Institu-
tional Review Board of our hospital.
Statistical analysis was performed using the Student’s t-test 
and the chi-square test using SPSS version 13.0 (SPSS Inc., Chi-
cago, IL, USA). Potential risk factors were assessed by univariate 
analysis on logistic regression and then a multivariate logistic 
regression model. Cumulative recurrence rates of bile duct 
stones during the follow-up intervals were compared using the 
Kaplan-Meier method. A p-value of less than 0.05 was consid-
ered statistically significant.
RESULTS
Demographic characteristics of the 209 patients are shown 
in Table 1. The gender ratio was similar in the two groups. The 
mean age was 70.9±10.3 years in the EPLBD+ES group and 
Table 1. Characteristics of Patients between the EPLBD+ES Group 
and the ES Group at the Time of the Initial ERCP
Characteristic
EPLBD+ES
(n=100)
ES
(n=109)
p-value
Mean age, yr 70.9±10.3 71.9±12.9 0.544
Sex, M/F 51/49 48/61 0.314
Previous cholecystectomy 22 (22.0) 25 (22.9) 0.871
Periampullary diverticulum 35 (47.3) 36 (33.0) 0.052
Billroth II gastrectomy 8 (8.0) 1 (0.9) 0.012
Mean number of stones 2.2±1.3 1.7±0.9 0.003
Mean diameter of stone, mm 16.4±6.7 14.0±4.6 0.003
Mean diameter of CBD, mm 21.1±5.7 19.6±5.6 0.060
Type of stones, brown/black  85/15 88/19 0.593
Values are presented as mean±SD or number (%).
EPLBD+ES, endoscopic papillary large balloon dilation combined 
with limited endoscopic sphincterotomy; ES, endoscopic sphincterot-
omy; ERCP, endoscopic retrograde cholangiopancreatography; CBD, 
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71.9±12.9 years in the ES group. Billroth II gastrectomy was 
documented in 8 patients (8.0%) in the EPLBD+ES group and 
one patient (0.9%) in the ES group (p=0.012). The mean num-
ber of stones was 2.2±1.3 in the EPLBD+ES group and 1.7±0.9 
in the ES group (p=0.003). The mean diameter of stones was 
16.4±6.7 mm in the EPLBD+ES group and 14.0±4.6 mm in 
the ES group (p=0.003). No significant differences in age, sex, 
previous cholecystectomy or periampullary diverticulum were 
observed between the EPLBD+ES and ES groups. The diameter 
of the CBD was 21.1±5.7 mm in the EPLBD+ES group and 
19.6±5.6 mm in the ES group; however, the difference between 
the two groups was not significant (p=0.060).
The duration of follow-up was 32.5±4.5 months (range, 22 
to 40 months) in the EPLBD+ES group and 31.8±6.0 months 
(range, 22 to 41 months) in the ES group. Of the 209 patients 
who underwent ERCP for choledocholithiasis, recurrent CBD 
stones appeared in 26 patients, with an overall recurrence rate 
of 12.4% during the follow-up period. The recurrence rate of 
CBD stones in the EPLBD+ES group was lower than that of the 
ES group; however, the difference was not significant (11.0% 
vs 13.8%, p=0.546) (Table 2). The mean interval between stone 
removal and stone recurrence in the EPLBD+ES and ES group 
was 17.2±11.8 months (range, 6 to 34 months) and 18.5±10.2 
months (range, 6 to 35 months), respectively (p=0.758). Kaplan-
Meier analysis revealed that the cumulative recurrence rate of 
bile duct stones between the EPLBD+ES group and the ES group 
was not significantly different (log rank, p=0.537) (Fig. 1).
A variety of possible risk factors associated with recurrence of 
bile duct stones, including age, sex, previous cholecystectomy, 
periampullary diverticulum, Billroth II gastrectomy, the size of 
the bile duct, angulation of bile duct, dilating balloon size, the 
number, size, and type of stones, and mechanical lithotripsy 
are listed in Table 3. On univariate analysis, the diameter of the 
CBD was found to be the only predictive variable that could dif-
ferentiate the recurrence group from the nonrecurrence group: 
the mean diameter of the CBD in the recurrence group was 
25.0±6.0 mm (range, 14.3 to 34 mm), whereas that of the non-
recurrence group was 20.6±5.6 mm (range, 10.9 to 35.5 mm) 
(p=0.022). The diameter of the CBD ≥22 mm was identified to 
be the predictive factor for the recurrence of stones. Multivariate 
analysis determined that the diameter of the CBD was the single 
risk factor to distinguish the recurrence group from the non-
recurrence group (p=0.022; odds ratio, 1.175; 95% confidence 
interval, 1.023 to 1.348). None of the variables previously men-
Table 2. Comparison of Patients with Recurrent Bile Duct Stones be-
tween the EPLBD+ES and the ES Groups at Follow-Up ERCP
Variable
EPLBD+ES
(n=100)
ES
(n=109)
p-value
Recurrence of CBD stones 11 (11.0) 15 (13.8) 0.546
Duration of follow-up, mo 32.5±4.5 
(22-40)
31.8±6.0 
(22-41)
0.334
Time interval between ERCP 
and stone recurrence, mo
17.2±11.8 
(6-34)
18.5±10.2 
(6-35)
0.758
Values are presented as the mean±SD (range) or number (%).
EPLBD+ES, e  ndoscopic papillary large-balloon dilation combined 
with limited endoscopic sphincterotomy; ES, endoscopic sphincterot-
omy; ERCP, endoscopic retrograde cholangiopancreatography; CBD, 
common bile duct.
Fig. 1. Kaplan-Meier plot for the cumulative recurrence rate of 
common bile duct stones in a total of 209 patients between the 
EPLBD+ES group and the ES group. No statistically significant differ-
ence was observed between the two groups (p=0.537, log-rank test). 
EPLBD+ES, endoscopic papillary large-balloon dilation combined 
with limited endoscopic sphincterotomy; ES, endoscopic sphincter-
otomy.
Table 3. Univariate Analysis of Risk Factors for Recurrent Bile Duct 
Stones after EPLBD+ES
Variable
Patients with 
recurrence
(n=11)
Patients with     
non-recurrence
(n=89)
p-
value
Mean age, yr 72.6±12.2 70.7±10.1 0.572
Sex, M/F 5/6 46/43 0.697
Previous cholecystectomy 2 (18.2) 20 (22.5) 0.746
Periampullary diverticulum 4 (36.4) 30 (50.0) 0.409
Billroth II gastrectomy 1 (9.1) 7 (7.9) 0.888
Mean number of stones   2.0±1.3   2.2±1.3 0.674
Mean diameter of stone, mm 18.4±5.8 16.3±6.8 0.326
Mean diameter of CBD, mm 25.0±6.0 20.6±5.6 0.022
CBD diameter
  ≥22 mm 8 (72.7) 33 (37.9) 0.039
  <22 mm 3 (27.3) 54 (62.1)
Distal CBD angulation, degree 139.6±21.1 142.9±18.4 0.602
Dilating balloon size, mm 16.6±1.6 17.3±1.6 0.227
Mechanical lithotripsy 1 (9.1) 3 (3.4) 0.381
Type of stones, brown/black 8/3 
(72.7/27.3)
77/12 
(86.5/13.5)
0.238
Values are presented as mean±SD or number (%).
EPLBD+ES, endoscopic papillary large-balloon dilation combined 
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tioned as not significant were able to provide any improvement 
to the final model.
DISCUSSION
Since introduction of endoscopic papillary large balloon 
dilatation combined with limited ES (EPLBD+ES), many stud-
ies of the effectiveness of sequential ES and EPBD have been 
published.
9,11-16 Currently, there are many descriptions of long-
term complications after ES, including cholangitis, recurrent bile 
duct stones, and biliary pancreatitis.
3,19,22 Reported incidence of 
recurrent choledocholithiasis after ES was 6% to 24%, and most 
recurrences occurred within the first 2 or 3 years after stone 
removal.
17,19-21 Meanwhile, EPBD demonstrated a similar rate of 
recurrence.
7,17,18 However, few studies on long-term follow-up 
results after EPLBD+ES have been reported.
Causes of recurrence of bile duct stones after ES are multi-
factorial: bile stasis, bacterial infection of the bile duct, and 
duodenocholedochal reflux are known to play crucial roles in 
pathogenesis of recurrent stone formation.
23,24 After ES, bile 
duct is susceptible to bacterial infection due to loss of sphincter 
function. Other studies have demonstrated that some bacterial 
species, e.g., E. coli, produce β-glucuronidase, which is a key 
enzyme in formation of brown pigment stones after sphicteroto-
my.
25,26 In our study, recurrent bile duct stones in the EPLBD+ES 
group, as well as the ES group, were mainly brown pigment 
stones, indicating that secondary bacterial infection of the bile 
duct via the patulous ampullary opening plays a major role in 
the process of stone recurrence. 
We postulated that, because EPLBD+ES could provide suf-
ficient enlargement for complete removal of bile duct stones 
compared with ES, recurrence of choledocholithiasis is expected 
to be reduced. In our study, the recurrence rate of CBD stones 
in the EPLBD+ES group was lower than that of the ES group, 
although not statistically significant. In the present study, uni-
variate and multivariate analysis determined that the diameter 
of the CBD was the only key factor accounting for the increased 
rate of recurrence of stones in the EPLBD+ES group. 
A higher stone recurrence was reported in the gallbladder 
in situ with stones in the EPBD group (14%) and a very low 
recurrence rate after cholecystectomy.
27 However, in our study, 
previous cholecystectomy was not associated with risk factors 
for recurrence. This finding is largely explained by the fact that 
recurrent stones in our cases were mostly brown stones, which 
were formed in the bile duct, rather than migrated from the 
gallbladder; thus, presence or absence of gallbladder appeared 
not to be associated with the risk of recurrence. Mechanical 
lithotripsy is frequently required for crushing large stones and 
is likely to increase the risk of recurrence because even a few 
missed tiny stone fragments may act as a nidus for stone reag-
gregation.
21 However, lithotripsy was not a significant risk fac-
tor for recurrence in the present study. The reasons might be as 
follows: First, use of mechanical lithotripsy was rarely required 
in EPLBD+ES, because the papillary orifice can be fully opened. 
Second, more complete clearance of stone debris might be 
achieved after stone fragmentation, owing to wider enlargement 
of the ampullary opening. Periampullary diverticula compress 
the distal CBD anatomically, leading to bile stasis, and, subse-
quently, cause bacterial infection of the bile duct via the Oddi 
orifice.
28 However, in our study, periampullary diverticulum was 
not found to be a risk factor for recurrent stones.
The degree of angulation along the course of CBD may con-
tribute to the bile stasis and thus cause recurrence of stones. A 
study have reported that an angulation (≤145 degree) of CBD 
is a risk factor for the recurrence of stones.
29 Meanwhile, other 
investigations demonstrated that distal angulation (≤135 degree) 
of bile duct was not associated with the recurrence of stones 
though it was a significant contributing factor to the technical 
difficulty of stone clearance.
30,31 In this study, the angulation of 
the CBD was not a significant risk factor for recurrence. In fact, 
the exact measurement of angulation has a technical limitation 
in patients with anatomical variation of bile duct on a 2-dimen-
sional plane. Balloon dilators, mainly 15 or 18 mm, were used 
to dilate the ampullary orifice. However, the size of balloons 
did not show a significant difference between the two groups. 
Size of the CBD is already known as an important predictor for 
recurrence of CBD stones. In the present study, the diameter 
of the CBD (≥22 mm) appears to be a risk factor for recurrent 
choledocholithiasis in the EPLBD+ES group. Costamagna et al.
20 
demonstrated that a bile duct diameter ≥22 mm was a prognos-
tic factor for choledocholithasis. Some authors have identified 
bile duct size >15 mm as a risk factor for recurrent stones.
18,21,32 
A dilated CBD is likely to lead to bile stasis and bacterial infec-
tion, which play central roles in the mechanism of stone for-
mation.
20,24,33 There are some possibilities of small fragmented 
stones missed by cholangiogram in patients with a large bile 
duct. 
In conclusion, although statistical significance was not ob-
served between the EPLBD+ES group and the ES group in terms 
of the recurrence rate, in our experience, the frequency of recur-
rent bile duct stones in the EPLBD+ES group was lower than 
that of the ES group. Large size of the CBD was identified as the 
only significant predictive factor for increasing the recurrence 
rate of bile duct stones in the EPLBD+ES group. This study, 
however, has the limitation of retrospective data; therefore, fur-
ther study is needed for investigation of the long-term outcome 
of EPLBD+ES. 
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